DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in the Asia pacific pharmaceutical markets (Australia, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand, and Vietnam). We report both the incidence and prevalence of cholangiocarcinoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at the first line of therapy is also forecast across the Asia pacific pharmaceutical markets.
DRG Epidemiology's cholangiocarcinoma forecast will answer the question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of cholangiocarcinoma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following cholangiocarcinoma subpopulations:
- Diagnosed incident cases— intrahepatic and extrahepatic cholangiocarcinoma
- Diagnosed prevalent cases — intrahepatic and extrahepatic cholangiocarcinoma.
- First-line drug-treatable cases – intrahepatic and extrahepatic cholangiocarcinoma
- … and more (details available on request).
Note: Coverage may vary by country.
- Cholangiocarcinoma - Epidemiology - Asia Pacific Data
- Key Findings
- Incidence of Intrahepatic Cholangiocarcinoma per 100,00 per Year Among People of All Ages in 2018 and 2028tttt
- Incidence of Extrahepatic Cholangiocarcinoma per 100,00 per Year Among People of All Ages in 2018 and 2028tttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Intrahepatic cholangiocarcinoma over the Next Ten Yearsttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Extrahepatic cholangiocarcinoma over the Next Ten Yearsttt
- Resectability Status of Cholangiocarcinoma Cases Across the Countries Under Study
- Epidemiology Data
- Newly Diagnosed Incidence
- Stage Distribution
- Recurrent Incidence
- Diagnosed Prevalence
- Drug-Treatable Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Cholangiocarcinoma
- Risk/Protective Factors
- Risk/Protective Factors for Cholangiocarcinoma
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.
Johnson Olabisi, M.B.B.S., M.Sc.
Johnson Olabisi, M.B.B.S., M.Sc., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he trained as a community physician. He has also supervised and coordinated various governmental and nongovernmental public health projects. He holds a master’s degree in public health (health economics) from the London School of Hygiene and Tropical Medicine, a master’s degree in epidemiology and medical statistics, and a medical degree from the University of Ibadan in Nigeria.